Potential role of flavonoids in the prevention of intestinal neoplasiaA review of their mode of action and their clinical perspectives

被引:48
作者
Harald P. Hoensch
Wilhelm Kirch
机构
[1] Community Hospital of Gross-Gerau,Department of Internal Medicine, Section of Gastroenterology
[2] Technical University of Dresden,Medical Faculty, Institut of Clinical Pharmacology
[3] Innere Abteilung,undefined
[4] Kreiskrankenhaus Gross-Gerau,undefined
来源
International Journal of Gastrointestinal Cancer | 2005年 / 35卷 / 3期
关键词
Flavonoids; intestinal neoplasia; nonsteroidal antiinflammatory drugs;
D O I
10.1385/IJGC:35:3:187
中图分类号
学科分类号
摘要
Intestinal neoplasia (adenomas and carcinomas) can possibly be prevented by a diet rich in vegetables and fruits, treatment with aspirin and other nonsteroidal antiinflammatory drugs, and early colonoscopic removal of adenomas. Ballast, fiber, and secondary plant products could play a major role in colon cancer prevention. Recently there has been much experimental work in vitro and in vivo about flavonoids as inducers of bioprevention. Flavonoids are secondary plant products with a wide variety of beneficial biological properties, and they possess anticarcinogenic, antimutagenic, and antioxidative modes of actions. Flavonoids are the main components of a healthy diet containing fruits and vegetables and are concentrated especially in tea, apples, and onions. We will focus this review on flavonoids which are derived from tea products such as proanthocyanidins (green tea) and flavons (camomille tea). Oral supplementation with bioflavonoids derived from tea could be used in humans to prevent growth of intestinal neoplasia such as adenomatous polyps of the colon. Flavonoids are a large group of natural compounds of which only a few have been used in animal models, cell cultures, and enzyme studies to inhibit mutagenic and carcinogenic events. Their clinical mode of action was evaluated by epidemiological studies, but no intervention studies in humans have been performed so far. In vitro flavonoids can bind electrophils, inactivate oxygen radicals, prevent lipid peroxidation, and inhibit DNA oxidation. In cell cultures they increase the rate of apoptosis, inhibit cell proliferation, and angiogenesis. In vivo they can induce the activities of protective enzymes (conjugating enzymes such as glutathione transferases and glucuronosyl transferases) of the intestine and the liver. In models of intestinal polyposis, flavonoids suppress polyp formation. Some epidemiological studies show a protective effect of flavonoids contained in fruits, vegetables, and tea.Flavonoid mixtures of tea origin supplied as nutritional supplements could be studied as a new way of bioprevention of intestinal neoplasia (colon adenomas and cancer). Therefore, a controlled, randomized clinical study should be performed to evaluate the efficacy of flavonoids.
引用
收藏
页码:187 / 195
页数:8
相关论文
共 150 条
[1]  
Bjelakovic G(2004)Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and metaanalysis Lancet 364 1219-1228
[2]  
Nikolova D(2004)New approaches to the role of diet in the prevention of cancers of the alimentary tract Mutat Res 551 9-28
[3]  
Simonetti RG(2004)Dietary cancer and prevention using antimutagens Toxicology 198 147-159
[4]  
Gluud C(2002)Dietary flavonols: chemistry, food content, and metabolism Nutrition 18 75-81
[5]  
Johnson IT(2002)Dietary flavonoids: bioavialability, metabolic effects and safety Ann Rev Nutr 22 19-34
[6]  
Ferguson LR(2002)Inhibition of carcinogenesis by tea Annu Rev Pharmacol Toxicol 33 237-253
[7]  
Philpott M(2003)Folate status, genomic DNA hypomethylation and risk of colorectal adenoma and cancer: a case control study Gastroenterology 124 1240-1248
[8]  
Karunasinghe N(2003)A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 891-899
[9]  
Aherne SA(2003)Daily soluble aspririn and prevention of colorectal adenome recurrence: one year results of the APACC trial Gastroenterology 125 328-336
[10]  
O’Brien NM(2003)The cyclooxygenase 2-inhibitors Rofecoxib and Celecoxib prevent colorectal neoplasia occurence Gastroenterology 125 404-421